Stent implantation has become a standard procedure for widening the narrowed or weakened (coronary) arteries. The stents promote vessel healing after the patients with coronary artery diseases have undergone the procedure of percutaneous coronary intervention (PCI), also known as angioplasty. Bio-engineered stents are used mainly for patients that have undergone substantial technological advances, albeit intermittently. Also known as antibody-coated stents, bio-engineered stents have gathered traction in treating patients with coronary artery stenosis who are at increased risk of restenosis.
Get Sample Copy of this Report @
Stent Implantation Gaining Traction in Managing Acute Coronary Syndrome
The clinical need for late stent thrombosis has accentuated the prospects of the bio-engineered stent market over the past few years. Numerous studies in the past few years have helped in expanding our understanding of the performance of these stents in managing acute coronary syndrome (ACS). Growing prevalence and morbidity of coronary heart diseases, especially in developed nations, is bolstering technological advances in bio-engineered stents. On the global level, health care systems are focusing on reducing the burden of cardiovascular diseases. This has also propelled advances in stenting technologies and placement techniques. All these factors have been driving the evolution of the bio-engineered stent market.
Bio-engineered stents have shown promise in patients who are at high risk of late thrombosis. In recent years, the stent type has been increasingly integrated with dual therapy stents. The popularity stems from its promising safety and efficacy in pro-vessel healing. A few randomized controlled trials have stirred developments in this direction, especially in Europe and the U.S. Further, increasing incidence of chronic kidney diseases and their significant prevalence worldwide have fueled the prospects of the bio-engineered stent market.
Read Comprehensive Overview of Report @
However, stringent regulatory frameworks especially in developing nations may prolong the launch of new products in the market. Nevertheless, the advent of novel coating strategies adopted for bio-engineered stents, notably with anti-CD34 antibody, has opened a new clinical avenue in the bio-engineered stent market.